title: In vivo evaluation of 4-[123I]iodo-N-[2[4-(6-trifluoromethyl-2-pyridinyl)-1-piperazinyl]ethyl]benzamide, a potential SPECT radioligand for the 5-HT1A receptor.
abstract: 4-[123I]Iodo-N-[2-[4-(6-trifluoromethyl-2-pyridinyl)-1-piperazinyl]ethyl]benzamide (1.123I), a potential SPECT 5-HT(1A) radioligand, was evaluated in vivo in rats. Biodistribution studies were performed leading to a % ID in the brain of 0.22 at 5 min p.i. No significant differences in % ID/g tissue of the different isolated brain regions (hippocampus, hypothalamus, striatum, cortex and cerebellum) could be demonstrated. Blocking experiments with 8-OH-DPAT, WAY100635 and ketanserin could not show any significant change in tracer uptake in the isolated brain regions. These data suggest that uptake in the brain does not represent binding of 1.123I to the 5-HT(1A) receptor.
authors.affiliation: Department of Radiopharmacy, Ghent University, Harelbekestraat 72, B-9000, Ghent, Belgium. marleen.vandecapelle@rug.ac.be
authors.forename: M
authors.initials: M
authors.lastname: Vandecapelle
authors.forename: F
authors.initials: F
authors.lastname: De Vos
authors.forename: H
authors.initials: H
authors.lastname: Vermeirsch
authors.forename: G
authors.initials: G
authors.lastname: De Ley
authors.forename: K
authors.initials: K
authors.lastname: Audenaert
authors.forename: D
authors.initials: D
authors.lastname: Leysen
authors.forename: R A
authors.initials: RA
authors.lastname: Dierckx
authors.forename: G
authors.initials: G
authors.lastname: Slegers
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000818:Animals; D001549:Benzamides / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D010879:Piperazines / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: C440008:4-iodo-N-(2-(4-(6-trifluoromethyl-2-pyridinyl)-1-piperazinyl)ethyl)benzamide; D001549:Benzamides; D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D007650:Ketanserin